Insider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) CAO Sells $635,278.80 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the transaction, the chief accounting officer now directly owns 494,774 shares in the company, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

William Frank Iv Hulse also recently made the following trade(s):

• On Thursday, March 13th, William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44.

MiMedx Group Trading Up 0.4 %

Shares of MDXG opened at $7.92 on Friday. The firm’s 50-day moving average price is $8.45 and its 200-day moving average price is $7.81. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.40 and a beta of 1.97. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently modified their holdings of the stock. IMG Wealth Management Inc. purchased a new position in MiMedx Group during the 4th quarter valued at about $28,000. Virtus Fund Advisers LLC purchased a new position in MiMedx Group during the 4th quarter valued at about $35,000. Van ECK Associates Corp purchased a new position in MiMedx Group during the 4th quarter valued at about $40,000. Point72 DIFC Ltd lifted its position in MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after acquiring an additional 2,837 shares during the period. Institutional investors own 79.15% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.